Metformine Hcl Cf

Metformin Hydrochloride, the active ingredient in Metformine Hcl Cf, is a biguanide presented as an oral tablet for the treatment of elevated blood glucose in adults with type 2 diabetes mellitus. It works by reducing hepatic glucose output and improving peripheral insulin sensitivity, helping to achieve glycaemic control.

GNH USA supplies Metformine Hcl Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Metformin Hydrochloride is used in the management of type 2 diabetes mellitus, a disorder of glucose metabolism.

- Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial glucose levels. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when used as an early intervention. - Gestational diabetes (when benefits outweigh risks): assists in controlling maternal blood glucose during pregnancy.

Metformin Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: usually when combined with insulin or sulfonylureas. - Vitamin B12 deficiency: may develop with long‑term use. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals. - Skin rash or hypersensitivity: including Stevens‑Johnson syndrome. - Acute pancreatitis: rare inflammatory condition of the pancreas.

Metformin Hydrochloride requires careful patient assessment and monitoring to minimise risks.

- Renal function assessment: avoid or adjust dose in patients with impaired kidney function. - Hepatic function monitoring: use cautiously in liver disease due to lactic acidosis risk. - Blood glucose monitoring: regular checks to avoid hypoglycaemia, especially with combination therapy. - Elderly patients: start at lower doses and monitor for accumulation. - Pregnancy and lactation: evaluate risk‑benefit ratio before prescribing. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations, heightening toxicity. - Alcohol: potentiates lactic acidosis, especially with chronic intake.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics (thiazides, loop): affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Digoxin: watch for altered plasma levels in renal impairment.